RhumbLine Advisers’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $137K | Buy |
13,171
+165
| +1% | +$1.71K | ﹤0.01% | 3422 |
|
|
2025
Q1 | $171K | Buy |
13,006
+2,805
| +27% | +$37K | ﹤0.01% | 3185 |
|
|
2024
Q4 | $183K | Buy |
10,201
+927
| +10% | +$16.6K | ﹤0.01% | 3240 |
|
|
2024
Q3 | $149K | Buy |
9,274
+787
| +9% | +$12.7K | ﹤0.01% | 3372 |
|
|
2024
Q2 | $229K | Buy |
8,487
+4,158
| +96% | +$112K | ﹤0.01% | 3146 |
|
|
2024
Q1 | $84.4K | Buy |
4,329
+78
| +2% | +$1.52K | ﹤0.01% | 3489 |
|
|
2023
Q4 | $87.9K | Buy |
4,251
+47
| +1% | +$971 | ﹤0.01% | 3489 |
|
|
2023
Q3 | $134K | Buy |
4,204
+211
| +5% | +$6.71K | ﹤0.01% | 3359 |
|
|
2023
Q2 | $134K | Buy |
+3,993
| New | +$134K | ﹤0.01% | 3416 |
|
|
2022
Q2 | – | Sell |
-3,618
| Closed | -$134K | – | 3213 |
|
|
2022
Q1 | $134K | Buy |
3,618
+2
| +0.1% | +$74 | ﹤0.01% | 2840 |
|
|
2021
Q4 | $354K | Buy |
3,616
+11
| +0.3% | +$1.08K | ﹤0.01% | 2650 |
|
|
2021
Q3 | $450K | Buy |
3,605
+98
| +3% | +$12.2K | ﹤0.01% | 2595 |
|
|
2021
Q2 | $440K | Buy |
3,507
+1,196
| +52% | +$150K | ﹤0.01% | 2619 |
|
|
2021
Q1 | $314K | Sell |
2,311
-56
| -2% | -$7.61K | ﹤0.01% | 2690 |
|
|
2020
Q4 | $215K | Buy |
2,367
+329
| +16% | +$29.9K | ﹤0.01% | 2810 |
|
|
2020
Q3 | $152K | Sell |
2,038
-440
| -18% | -$32.8K | ﹤0.01% | 2768 |
|
|
2020
Q2 | $211K | Buy |
+2,478
| New | +$211K | ﹤0.01% | 2745 |
|
|
2019
Q2 | – | Sell |
-1,139
| Closed | -$81K | – | 3002 |
|
|
2019
Q1 | $81K | Buy |
1,139
+346
| +44% | +$24.6K | ﹤0.01% | 2885 |
|
|
2018
Q4 | $63K | Buy |
793
+265
| +50% | +$21.1K | ﹤0.01% | 2924 |
|
|
2018
Q3 | $246K | Sell |
528
-32
| -6% | -$14.9K | ﹤0.01% | 2621 |
|
|
2018
Q2 | $222K | Buy |
560
+170
| +44% | +$67.4K | ﹤0.01% | 2686 |
|
|
2018
Q1 | $119K | Buy |
390
+35
| +10% | +$10.7K | ﹤0.01% | 2715 |
|
|
2017
Q4 | $105K | Sell |
355
-59
| -14% | -$17.5K | ﹤0.01% | 2767 |
|
|
2017
Q3 | $227K | Buy |
414
+12
| +3% | +$6.58K | ﹤0.01% | 2673 |
|
|
2017
Q2 | $239K | Buy |
+402
| New | +$239K | ﹤0.01% | 2670 |
|